Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X:
“Phase 3 COMPETE trial just published in the Lancet
[¹⁷⁷Lu] Lu-edotreotide significantly outperforms everolimus in advanced, progressive somatostatin receptor-positive GEP-NETs.
Median PFS: 23.9 months vs 14.1 months (stratified HR 0.67, p=0.022)
How might this reshape treatment sequencing for progressive GEP-NETs?
Key secondary results:
- Objective response rate 22% vs 4% (p<0.0001).
- Disease control similar, but median duration longer with PRRT.
- Safety favoured [¹⁷⁷Lu]Lu-edotreotide: treatment-related grade 3–4 adverse events in 18% vs 40%.
- No treatment-related deaths in either group.
Concomitant somatostatin analogues allowed only for symptom control.”
Title: [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial
Authors: Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard Baum, Hein Verberne, Jarosław Ćwikła, Rajaventhan Srirajaskanthan, Louis de Mestier, Chiara Grana, Andreas Buck, Dieter Hörsch, Marianne Pavel, Lawrence Dierickx, Michael Michael, Jonathan Strosberg, Attila Kollár, Paula Jimenez-Fonseca, Anja Rinke, Maribel del Olmo-García, Anthime Flaus, Jorge Hernando, Andreas Kluge, Monika Breuninger, Serhii Melnyk, Konstantin Zhernosekov, Jaume Capdevila
Read the Full Article on The Lancet
Other articles featuring Parham Habibzadeh on OncoDaily
